NMDA Receptors Containing the Glun2d Subunit Control Neuronal Function in the Subthalamic Nucleus

Total Page:16

File Type:pdf, Size:1020Kb

NMDA Receptors Containing the Glun2d Subunit Control Neuronal Function in the Subthalamic Nucleus The Journal of Neuroscience, December 2, 2015 • 35(48):15971–15983 • 15971 Cellular/Molecular NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus X Sharon A. Swanger,1* Katie M. Vance,1* Jean-Franc¸ois Pare,3 Florence Sotty,4 Karina Fog,4 Yoland Smith,2,3 and X Stephen F. Traynelis1 1Department of Pharmacology and 2Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30322, 3Yerkes National Primate Research Center and Morris K. Udall Center of Excellence for Parkinson’s Disease Research, Emory University, Atlanta, Georgia 30329, and 4H. Lundbeck A/S, Division of Neurodegeneration and Biologics, Ottiliavej 9, DK-2500 Valby, Denmark The GluN2D subunit of the NMDA receptor is prominently expressed in the basal ganglia and associated brainstem nuclei, including the subthalamic nucleus (STN), globus pallidus, striatum, and substantia nigra. However, little is known about how GluN2D-containing NMDA receptors contribute to synaptic activity in these regions. Using Western blotting of STN tissue punches, we demonstrated that GluN2D is expressed in the rat STN throughout development [age postnatal day 7 (P7)–P60] and in the adult (age P120). Immunoelectron microscopy of the adult rat brain showed that GluN2D is predominantly expressed in dendrites, unmyelinated axons, and axon terminals within the STN. Using subunit-selective allosteric modulators of NMDA receptors (TCN-201, ifenprodil, CIQ, and DQP-1105), we provide evidence that receptors containing the GluN2B and GluN2D subunits mediate responses to exogenously applied NMDA and glycine, as well as synaptic NMDA receptor activation in the STN of rat brain slices. EPSCs in the STN were mediated primarily by AMPA and NMDA receptors and GluN2D-containing NMDA receptors controlled the slow deactivation time course of EPSCs in the STN. In vivo recordings from the STN of anesthetized adult rats demonstrated that the spike firing rate was increased by the GluN2C/D potentiator CIQ and decreased by the GluN2C/D antagonist DQP-1105, suggesting that NMDA receptor activity can influence STN output. These data indicate that the GluN2B and GluN2D NMDA receptor subunits contribute to synaptic activity in the STN and may represent potential therapeutic targets for modulating subthalamic neuron activity in neurological disorders such as Parkinson’s disease. Key words: excitatory synapse; GluN2B; GluN2D; glutamate receptor; NMDA; subthalamic nucleus Significance Statement The subthalamic nucleus (STN) is a key component of the basal ganglia, a group of subcortical nuclei that control movement and are dysregulated in movement disorders such as Parkinson’s disease. Subthalamic neurons receive direct excitatory input, but the pharmacology of excitatory synaptic transmission in the STN has been understudied. Here, we show that GluN2B- and GluN2D- containing NMDA receptors mediate the NMDA receptor component of EPSCs in subthalamic neurons. Moreover, our results demonstrate that pharmacologic modulation of GluN2D-containing receptors alters the time course of EPSCs and controls the in vivo spike-firing rate in the STN. This study identifies GluN2D as a potential target for modulating subthalamic neuron activity. Introduction nuclei that are critical for movement control. Neuronal activity in The subthalamic nucleus (STN) is the lone glutamatergic mem- the STN provides the primary excitatory drive for the basal gan- ber of the basal ganglia, a group of interconnected subcortical glia output nuclei, the globus pallidus internal, and substantia nigra pars reticulata (SNr; Bolam et al., 2000; Bevan et al., 2002; Wilson and Bevan, 2011). STN neurons exhibit autonomous fir- Received April 30, 2015; revised Oct. 20, 2015; accepted Oct. 29, 2015. ing that is driven by voltage-dependent sodium channels (Beur- Author contributions: S.A.S., K.M.V., J.-F.P., F.S., K.F., Y.S., and S.F.T. designed research; S.A.S., K.M.V., J.-F.P., and F.S. performed research; S.A.S., K.M.V., J.-F.P., F.S., K.F., Y.S., and S.F.T. analyzed data; S.A.S., K.M.V., F.S., K.F., rier et al., 2000; Do and Bean, 2003; Surmeier et al., 2005; Y.S., and S.F.T. wrote the paper. Atherton et al., 2008). Spike firing of subthalamic neurons is also WethankSusanJenkinsforherhelpwithimmunocytochemistryandtissueprocessing,andStefanieRitterforher help with the GluN2D antibody. We also thank Jing Zhang, Anel Tankovic, and Phuong Le for excellent technical assistance. This work was supported by the NIH-NINDS [NS036654 and NS065371 (SFT), F32-NS086368 (SAS), *S.A.S. and K.M.V. contributed equally to this work. T32-NS007480 (KMV)], NIH-NIDA T32-DA015040 (SAS and KMV), The Michael J. Fox Foundation (SFT), and a re- Correspondence should be addressed to Dr. Stephen F. Traynelis, Department of Pharmacology, Rollins Research search grant to Emory University from Lundbeck A/S (SFT). Center, Emory University School of Medicine, 1510 Clifton Rd., Atlanta, GA 30322. E-mail: [email protected]. S.F.T. is a paid consultant for NeurOp and Janssen Pharmaceuticals and holds an equity position at NeurOp. The DOI:10.1523/JNEUROSCI.1702-15.2015 remaining authors declare no competing financial interests. Copyright © 2015 the authors 0270-6474/15/3515971-13$15.00/0 15972 • J. Neurosci., December 2, 2015 • 35(48):15971–15983 Swanger, Vance et al. • GluN2D Function in the Subthalamic Nucleus regulated by several types of afferents, including excitatory inputs Materials and Methods from the cortex, thalamus, pedunculopontine nucleus, and supe- Tissue punches and Western blotting. All procedures using animals were rior colliculus (Afsharpour, 1985; Canteras et al., 1988; Fe´ger et approved by the Institutional Animal Care and Use Committee of Emory al., 1994; Nambu et al., 1996; Fe´ger, 1997). STN neurons also University. Female Sprague Dawley rats [age postnatal day 7 (P7), P14, Ϫ Ϫ recieve inhibitory inputs from the globus pallidus external P30, P60, and P110–P120] and WT and GluN2D / C57BL/6 mice of (Smith and Grace, 1992; Shink et al., 1996; Bolam et al., 2002; both sexes (age P28–P30) were killed by isoflurane overdose (Ikeda et al., ␮ Karachi et al., 2005) and dopaminergic inputs from the substan- 1995). The brains were removed and 200–300 m sagittal slices contain- ing the STN were prepared in ice-cold PBS using a vibrating microtome. tia nigra pars compacta (SNc) (Hassani et al., 1997; Prensa et al., Tissue punches of the STN were removed using a 0.5 or 0.75 mm tissue 2000; Cragg et al., 2004). The loss of SNc neurons in Parkinson’s punch (Stoelting) and then frozen on dry ice. The tissue was sonicated in disease leads to altered firing patterns in the STN, which corre- lysis buffer, pH 7.4, containing the following (in mM): 150 NaCl, 50 Tris, lates with the development of motor symptoms in patients and in 50 NaF, 5 EDTA, 5 EGTA, 1% Triton, 1% SDS, and protease inhibitors. animal models of the disease (Hamani et al., 2004; Wilson and Protein concentrations were determined by the Bradford assay and then Bevan, 2011). In addition, synchronous firing between the STN the samples were diluted with lysis buffer and 2ϫ Laemmli buffer to a and motor cortex increases in the disease state, suggesting that final concentration of 0.5 ␮g/␮l. After heating at 95°C for 5 min, 5–10 ␮g activity at glutamatergic cortical inputs to the STN may be altered of total protein was loaded on a 4–15% SDS-PAGE gel. Proteins were transferred to PVDF membranes for Western blotting. The antibodies (Magill et al., 2001; Magill et al., 2004; Sharott et al., 2005; Ku¨hn used were mouse anti-GluN2D (Millipore, MAB5578, 1:5000), mouse et al., 2006; Mallet et al., 2008; Litvak et al., 2011; Moran et al., anti-tubulin (Sigma-Aldrich, 1:50,000), and HRP-conjugated goat anti- 2011; Alegre and Valencia, 2013). Furthermore, exogenous acti- mouse (Jackson Immunoresearch, 1:10,000). Membranes were stripped vation of the corticosubthalamic projection can induce parkin- with Restore Stripping Buffer (Pierce) for 15 min and washed before sonian motor symptoms in rodents (Pan et al., 2014), indicating being reprobed with additional primary antibodies. Chemiluminescence that glutamatergic neurotransmission in the STN has an integral signals were detected with film, which were imaged with the Bio-Rad Gel role in basal ganglia function and movement. Doc Imager and analyzed by densitometry using ImageJ. Subthalamic neurons express mRNA encoding subunits in Immunohistochemistry and electron microscopy. Adult Sprague Dawley rats and adult WT and GluN2D Ϫ/Ϫ C57BL/6 mice of both sexes were each ionotropic glutamate receptor class, including AMPA, kai- used for histology experiments. The animals were anesthetized with pen- nate, and NMDA receptors (Sato et al., 1993; Bischoff et al., 1997; tobarbital and perfusion fixed with a mixture of 4% paraformaldehyde Wu¨llner et al., 1997; Clarke and Bolam, 1998; Jakowec et al., and 0.1% glutaraldehyde (Galvan et al., 2006; Kuwajima et al., 2007). The 1998). AMPA/kainate-type receptors mediate the fast compo- brains were then cut into 60-␮m-thick sections with a vibratome and nent of EPSCs, whereas NMDA receptors mediate the slow com- processed for the light and electron microscopic localization of the ponent, which carries the majority of charge transfer and calcium GluN2D subunit using well characterized commercially available anti- influx during excitatory neurotransmission (Traynelis et al., bodies: mouse anti-GluN2D (Millipore, MAB5578) or goat anti- 2010). NMDA receptors are typically composed of two glycine- GluN2C/D (Santa Cruz Biotechnology, sc-31551; Laurie et al., 1997). Ј binding GluN1 subunits and two glutamate-binding GluN2 sub- The avidin–biotin peroxidase method and 3,3 diaminobenzidine were used to visualize the reaction product of GluN2D immunoreactivity. units (Dingledine et al., 1999; Karakas and Furukawa, 2014; Lee et Sections of the STN were prepared for electron microscopy as previously al., 2014).
Recommended publications
  • Prevention Or Amelioration of Autism-Like Symptoms in Animal Models: Will It Bring Us Closer to Treating Human ASD?
    International Journal of Molecular Sciences Review Prevention or Amelioration of Autism-Like Symptoms in Animal Models: Will it Bring Us Closer to Treating Human ASD? Asher Ornoy 1,* , Liza Weinstein-Fudim 1 and Zivanit Ergaz 1,2 1 Laboratory of Teratology, Department of Medical Neurobiology, Hebrew University Hadassah Medical School, Jerusalem 9112001, Israel; [email protected] 2 Neonatology Department, Hadassah Hebrew University Medical Center, Jerusalem 9112001, Israel; [email protected] * Correspondence: [email protected]; Tel.: +972-2-6758329 Received: 17 February 2019; Accepted: 23 February 2019; Published: 1 March 2019 Abstract: Since the first animal model of valproic acid (VPA) induced autistic-like behavior, many genetic and non-genetic experimental animal models for Autism Spectrum Disorder (ASD) have been described. The more common non-genetic animal models induce ASD in rats and mice by infection/inflammation or the prenatal or early postnatal administration of VPA. Through the establishment of these models, attempts have been made to ameliorate or even prevent ASD-like symptoms. Some of the genetic models have been successfully treated by genetic manipulations or the manipulation of neurotransmission. Different antioxidants have been used (i.e., astaxanthin, green tea, piperine) to reduce brain oxidative stress in VPA-induced ASD models. Agents affecting brain neurotransmitters (donepezil, agmatine, agomelatine, memantine, oxytocin) also successfully reduced ASD-like symptoms. However, complete prevention of the development of symptoms was achieved only rarely. In our recent study, we treated mouse offspring exposed on postnatal day four to VPA with S-adenosine methionine (SAM) for three days, and prevented ASD-like behavior, brain oxidative stress, and the changes in gene expression induced by VPA.
    [Show full text]
  • GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine
    Neuropsychopharmacology (2017) 42, 1231–1242 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine 1,5 1,5 1,2 1 1 1 Rong-Jian Liu , Catharine Duman , Taro Kato , Brendan Hare , Dora Lopresto , Eunyoung Bang , 3 3,4 1 1 *,1 Jeffery Burgdorf , Joseph Moskal , Jane Taylor , George Aghajanian and Ronald S Duman 1Departments of Psychiatry and Neurosciences, Yale University School of Medicine, New Haven, CT, USA; 2Sumitomo Dainippon Pharma Co, Suita, 3 Osaka, Japan; Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston IL, USA; 4 Naurex, Inc., Evanston, IL, USA GLYX-13 is a putative NMDA receptor modulator with glycine-site partial agonist properties that produces rapid antidepressant effects, but without the psychotomimetic side effects of ketamine. Studies were conducted to examine the molecular, cellular, and behavioral actions of GLYX-13 to further characterize the mechanisms underlying the antidepressant actions of this agent. The results demonstrate that a single dose of GLYX-13 rapidly activates the mTORC1 pathway in the prefrontal cortex (PFC), and that infusion of the selective mTORC1 inhibitor rapamycin into the medial PFC (mPFC) blocks the antidepressant behavioral actions of GLYX-13, indicating a requirement for mTORC1 similar to ketamine. The results also demonstrate that GLYX-13 rapidly increases the number and function of spine synapses in the apical dendritic tuft of layer V pyramidal neurons in the mPFC. Notably, GLYX-13 significantly increased the synaptic responses to hypocretin, a measure of thalamocortical synapses, compared with its effects on 5-HT responses, a measure of cortical- cortical responses mediated by the 5-HT receptor.
    [Show full text]
  • A Systematic Review of Performance-Enhancing Pharmacologicals and Biotechnologies in the Army
    Bond University Research Repository A systematic review of performance-enhancing pharmacologicals and biotechnologies in the Army Ko, Henry ; Hunter, K E; Scott, A M; Ayson, Mark; Willson, M L Published in: Journal of the Royal Army Medical Corps DOI: 10.1136/jramc-2016-000752 Licence: CC BY-NC Link to output in Bond University research repository. Recommended citation(APA): Ko, H., Hunter, K. E., Scott, A. M., Ayson, M., & Willson, M. L. (2018). A systematic review of performance- enhancing pharmacologicals and biotechnologies in the Army. Journal of the Royal Army Medical Corps, 164(3). https://doi.org/10.1136/jramc-2016-000752 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator. Download date: 06 Oct 2021 ABSTRACT Introduction: In 2015, the Australian Army commissioned a systematic review to assess the evidence on effectiveness and safety of pharmacological and biotechnological products for cognitive enhancement specifically in Army personnel. Methods: Searches for studies examining biotechnological and pharmacological products in Army populations were conducted in December 2015. Cochrane CENTRAL, MEDLINE, EMBASE, CINAHL and PsycINFO were searched; no date or language restrictions were applied. WHO’s International Clinical Trials Registry Platform and ClinicalTrials.gov were searched to identify ongoing trials. Studies meeting inclusion criteria were evaluated for risk of bias using the Cochrane Risk of Bias tool.
    [Show full text]
  • Novel Therapeutic Strategies in Parkinson's Disease
    Novel therapeutic strategies in Parkinson’s disease Peter Klivenyi, Laszlo Vecsei To cite this version: Peter Klivenyi, Laszlo Vecsei. Novel therapeutic strategies in Parkinson’s disease. European Journal of Clinical Pharmacology, Springer Verlag, 2009, 66 (2), pp.119-125. 10.1007/s00228-009-0742-4. hal-00535002 HAL Id: hal-00535002 https://hal.archives-ouvertes.fr/hal-00535002 Submitted on 11 Nov 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Eur J Clin Pharmacol (2010) 66:119–125 DOI 10.1007/s00228-009-0742-4 REVIEW ARTICLE Novel therapeutic strategies in Parkinson’s disease Peter Klivenyi & Laszlo Vecsei Received: 30 June 2009 /Accepted: 30 September 2009 /Published online: 16 October 2009 # Springer-Verlag 2009 Introduction producing symptomatic benefit. However, in the subse- quent human clinical trials, many of them failed to produce Parkinson’s disease (PD) is a neurodegenerative disorder the same efficacy as seen in preclinical studies. These characterized by resting tremor, rigidity, and bradykinesia. failures are not necessarily an indication of drug failure or The pathological processes begin years/decades before the drug action but may be related to inadequate administration, first motor symptoms are observed.
    [Show full text]
  • Neurotransmission Product Guide | Edition 1
    Neurotransmission Product Guide | Edition 1 Delphinium Delphinium A source of Methyllycaconitine Contents by Research Area: • Dopaminergic Transmission • Glutamatergic Transmission • Opioid Peptide Transmission • Serotonergic Transmission • Chemogenetics Tocris Product Guide Series Neurotransmission Research Contents Page Principles of Neurotransmission 3 Dopaminergic Transmission 5 Glutamatergic Transmission 6 Opioid Peptide Transmission 8 Serotonergic Transmission 10 Chemogenetics in Neurotransmission Research 12 Depression 14 Addiction 18 Epilepsy 20 List of Acronyms 22 Neurotransmission Research Products 23 Featured Publications and Further Reading 34 Introduction Neurotransmission, or synaptic transmission, refers to the passage of signals from one neuron to another, allowing the spread of information via the propagation of action potentials. This process is the basis of communication between neurons within, and between, the peripheral and central nervous systems, and is vital for memory and cognition, muscle contraction and co-ordination of organ function. The following guide outlines the principles of dopaminergic, opioid, glutamatergic and serotonergic transmission, as well as providing a brief outline of how neurotransmission can be investigated in a range of neurological disorders. Included in this guide are key products for the study of neurotransmission, targeting different neurotransmitter systems. The use of small molecules to interrogate neuronal circuits has led to a better understanding of the under- lying mechanisms of disease states associated with neurotransmission, and has highlighted new avenues for treat- ment. Tocris provides an innovative range of high performance life science reagents for use in neurotransmission research, equipping researchers with the latest tools to investigate neuronal network signaling in health and disease. A selection of relevant products can be found on pages 23-33.
    [Show full text]
  • Neonatal Administration of Memantine Enhances Social Cognition in Adult Rats Subjected to Early Maternal Deprivation
    https://doi.org/10.5607/en.2016.25.6.328 Exp Neurobiol. 2016 Dec;25(6):328-332. pISSN 1226-2560 • eISSN 2093-8144 Original Article Neonatal Administration of Memantine Enhances Social Cognition in Adult Rats Subjected to Early Maternal Deprivation Ezequiel Uribe*, Eduardo Sánchez-Mendoza, Nayadoleni Nieves and Gustavo Merchor Biophysics and Neuroscience Center, Behavioral Neurobiology Laboratory, Biomedical and Technological Sciences, University of Carabobo, Valencia, Venezuela Schizophrenia is considered a neurodevelopmental disorder; however, all the available treatment options are used when the disease becomes clinically significant in adolescence or early adulthood. Using a developmental rat model of schizophrenia, we examined whether neonatal treatment with memantine, an NMDA receptor modulator, can improve schizophrenic-like symptoms in adulthood. Early maternal deprivation in rats produces deficits in social interaction behaviors in adulthood. In contrast, memantine administrated in neonatal rats subjected to early maternal deprivation significantly reduces deficits in social interaction behaviors in adulthood. These results raise the possibility that pharmacological treatment with memantine at the early developmental stage helps people with a risk to develop schizophrenic-like symptoms. Key words: Schizophrenia, neuropharmacology, developing brain, glutamate, social cognition, neonatal INTRODUCTION begin before adolescence but becomes clinically significant in this period; probably during prefrontal cortex maturation [5]. Schizophrenia is considered a neurodevelopmental disorder, SC is a prefrontal function referred to the capacity of identify with onset during adolescence or early adulthood in 80% of cases the mental status about conspecifics, which depend of a correct [1]. It shows no clear signs of behavioral dysfunction during glutamatergic transmission [6], widely impaired in schizophrenia childhood; social isolation is frequent during prodromal period [7].
    [Show full text]
  • Review Article Cell Cycle Inhibition Without Disruption of Neurogenesis Is a Strategy for Treatment of Aberrant Cell Cycle Diseases: an Update
    The Scientific World Journal Volume 2012, Article ID 491737, 13 pages The cientificWorldJOURNAL doi:10.1100/2012/491737 Review Article Cell Cycle Inhibition without Disruption of Neurogenesis Is a Strategy for Treatment of Aberrant Cell Cycle Diseases: An Update Da-Zhi Liu and Bradley P. Ander Department of Neurology and the MIND Institute, University of California at Davis, Sacramento, CA 95817, USA Correspondence should be addressed to Da-Zhi Liu, [email protected] Received 13 October 2011; Accepted 17 November 2011 Academic Editors: F. Bareyre and B. K. Jin Copyright © 2012 D.-Z. Liu and B. P. Ander. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Since publishing our earlier report describing a strategy for the treatment of central nervous system (CNS) diseases by inhibiting the cell cycle and without disrupting neurogenesis (Liu et al. 2010), we now update and extend this strategy to applications in the treatment of cancers as well. Here, we put forth the concept of “aberrant cell cycle diseases” to include both cancer and CNS diseases, the two unrelated disease types on the surface, by focusing on a common mechanism in each aberrant cell cycle reentry. In this paper, we also summarize the pharmacological approaches that interfere with classical cell cycle molecules and mitogenic pathways to block the cell cycle of tumor cells (in treatment of cancer) as well as to block the cell cycle of neurons (in treatment of CNS diseases). Since cell cycle inhibition can also block proliferation of neural progenitor cells (NPCs) and thus impair brain neurogenesis leading to cognitive deficits, we propose that future strategies aimed at cell cycle inhibition in treatment of aberrant cell cycle diseases (i.e., cancers or CNS diseases) should be designed with consideration of the important side effects on normal neurogenesis and cognition.
    [Show full text]
  • NYX-2925 Is a Novel N-Methyl-D-Aspartate Receptor Modulator That Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain
    1521-0103/366/3/485–497$35.00 https://doi.org/10.1124/jpet.118.249409 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:485–497, September 2018 Copyright ª 2018 The Author(s). This is an open access article distributed under the CC BY Attribution 4.0 International license. NYX-2925 Is a Novel N-Methyl-D-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain Nayereh Ghoreishi-Haack, Jessica M. Priebe, Jacqueline D. Aguado, Elizabeth M. Colechio, Jeffrey S. Burgdorf, M. Scott Bowers, Cassia N. Cearley, M. Amin Khan, and Joseph R. Moskal Aptinyx, Inc., Evanston, Illinois (N.G.-H., J.M.P., J.D.A., E.M.C., J.S.B., M.S.B., C.N.C., M.A.K., J.R.M.) and Falk Center for Molecular Therapeutics, Department of Biomedical Engineering, Northwestern University, Evanston, Illinois (J.S.B., M.S.B., Downloaded from J.R.M.) Received April 4, 2018; accepted July 3, 2018 ABSTRACT NYX-2925 [(2S,3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5- and formalin-induced persistent pain, but was ineffective in jpet.aspetjournals.org diazaspiro[3.4]octan-2-yl)butanamide] is a novel N-methyl-D- the tail flick model. The analgesic effects of NYX-2925 were aspartate (NMDA) receptor modulator that is currently being blocked by the systemic administration of NMDA receptor investigated in phase 2 clinical studies for the treatment of antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic painful diabetic peripheral neuropathy and fibromyalgia.
    [Show full text]
  • Research Article
    Available Online at http://www.recentscientific.com International Journal of CODEN: IJRSFP (USA) Recent Scientific International Journal of Recent Scientific Research Research Vol. 9, Issue, 6(E), pp. 27560-27565, June, 2018 ISSN: 0976-3031 DOI: 10.24327/IJRSR Research Article BIOSYNTHESIS OF NEUROSTEROID AND PHARMACOLOGYCAL ACTION Vandna Dewangan*., Trilochan Satapthy and Ram Sahu Department of Pharmacology, Columbia Institute of Pharmacy, Tekari, Near Vidhansabha, Raipur-493111(C.G.) India DOI: http://dx.doi.org/10.24327/ijrsr.2018.0906.2285 ARTICLE INFO ABSTRACT Article History: Over the past decade, it has become clear that the brain, like the gonad, adrenal and placenta, is a steroid genic organ. Neurosteroids are synthetized in the central and the peripheral nervous system, Received 20th March, 2018 in glial cells, and also in neurons, from cholesterol or steroidal precursors imported from peripheral Received in revised form 27th sources. However, unlike classic steroid genic tissues, the synthesis of steroids in the nervous April, 2018 system requires the coordinate expression and regulation of the genes encoding the steroid genic Accepted 5th May, 2018 enzymes in several different cell types (neurons and glia) at different locations in the nervous Published online 28th June, 2018 system, and at distances from the cell bodies. The steroids synthesized by the brain and nervous system, given the name neurosteroids Progesterone itself is also a neurosteroid, and a progesterone Key Words: receptor has been detected in peripheral and central glial cells. At different sites in the brain, Neurosteroid, Steroid hormones, neurosteroid concentrations vary according to environmental and behavioural circumstances, such as Progesterone, Glial Cell, Nuclear receptor, stress, sex recognition, or aggressiveness.
    [Show full text]
  • Animal Models of Schizophrenia
    British Journal of DOI:10.1111/j.1476-5381.2011.01386.x www.brjpharmacol.org BJP Pharmacology Themed Issue: Translational Neuropharmacology – Using Appropriate Animal Models to Guide Clinical Drug Development Correspondence Professor Kevin Fone, School of Biomedical Sciences, Medical School, Queen’s Medical Centre, REVIEWbph_1386 1162..1194 The University of Nottingham, Nottingham NG7 2UH, UK. E-mail: Animal models of [email protected] ---------------------------------------------------------------- Keywords schizophrenia schizophrenia; animal model; antipsychotics; isolation rearing; ventral hippocampal lesion; CA Jones, DJG Watson and KCF Fone reelin; DISC-1; neuregulin; dysbindin; phencyclidine School of Biomedical Sciences, Medical School, Queen’s Medical Centre, The University of ---------------------------------------------------------------- Nottingham, Nottingham, UK Received 23 November 2010 Revised 9 March 2011 Accepted 12 March 2011 Developing reliable, predictive animal models for complex psychiatric disorders, such as schizophrenia, is essential to increase our understanding of the neurobiological basis of the disorder and for the development of novel drugs with improved therapeutic efficacy. All available animal models of schizophrenia fit into four different induction categories: developmental, drug-induced, lesion or genetic manipulation, and the best characterized examples of each type are reviewed herein. Most rodent models have behavioural phenotype changes that resemble ‘positive-like’ symptoms of schizophrenia,
    [Show full text]
  • Yale University School of Medicine Human Investigation Committee
    Approved - Valid through 23-JUN-2017 YALE UNIVERSITY SCHOOL OF MEDICINE HUMAN INVESTIGATION COMMITTEE Application to Involve Human Subjects in Research ECTION DMINISTRATIVE NFORMATION S I: A I Title of Research Project: Glutamate-opioid interactions in alcohol drinking behaviors Principal Investigator: Yale Academic Appointment: Suchitra Krishnan-Sarin, Ph.D. Associate Professor Campus Address: S-208, 34 Park Street, New Haven, CT 06519 Campus Phone: Fax: Pager: E-mail: 203-974-7595 203-974-7606 [email protected] Protocol Correspondent Name & Address (if different than PI): Dana Cavallo, 34 Park Street, New Haven CT 06519 Campus Phone: Fax: E-mail: 203-974-7607 203-974-7606 [email protected] Faculty Advisor:(required if PI is a student, tment: resident, fellow or other trainee) N Campus Address: Campus Phone: Fax: Pager: E-mail: SECTION II: GENERAL INFORMATION 1. Performing Organizations: Identify the hospital, in-patient or outpatient facility, school or other agency that will serve as the location of the research. Choose all that apply: a. Internal Location[s] of the Study: Magnetic Resonance Research Center PET Center (MR-TAC) YCCI/Church Street Research Unit (CSRU) Yale Cancer Center YCCI/Hospital Research Unit (HRU) Yale-New Haven Hospital YCCI/Keck Laboratories Specify Other Yale Location Cancer Data Repository/Tumor Registry b. External Location[s]: APT Foundation, Inc. Haskins Laboratories Connecticut Mental Health Center John B. Pierce Laboratory, Inc. Veterans Affairs Hospital, West Haven Other Locations, Specify: CMU c. Additional Required Documents (check all that apply): N/A *YCCI-Scientific and Safety Committee (YCCI-SSC) Approval Date: *Pediatric Protocol Review Committee (PPRC) Approval Date: Page 1 of 52 APPROVED BY THE YALE UNIVERSITY HIC ON 07-DEC-2016 Approved - Valid through 23-JUN-2017 *YCC Protocol Review Committee (YRC-PRC)Approval Date: *Dept.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]